{"id":177047,"date":"2025-10-15T15:59:14","date_gmt":"2025-10-15T15:59:14","guid":{"rendered":"https:\/\/teknomers.com\/en\/drinking-without-getting-drunk-the-family-of-drugs-known-as-ozempic-shows-that-they-can-reduce-the-effects-of-alcohol-on-the-brain\/"},"modified":"2025-10-15T15:59:14","modified_gmt":"2025-10-15T15:59:14","slug":"drinking-without-getting-drunk-the-family-of-drugs-known-as-ozempic-shows-that-they-can-reduce-the-effects-of-alcohol-on-the-brain","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/drinking-without-getting-drunk-the-family-of-drugs-known-as-ozempic-shows-that-they-can-reduce-the-effects-of-alcohol-on-the-brain\/","title":{"rendered":"Drinking without getting drunk? The family of drugs known as Ozempic shows that they can reduce the effects of alcohol on the brain."},"content":{"rendered":"\n
\n

Exploring the Future of Alcohol Consumption with GLP-1 Medications<\/h2>\n

Imagine a world where you can enjoy a drink without worrying about \u00a0getting drunk\u00a0. The possibility of \u00a0moderating alcohol consumption\u00a0 may soon become a reality with the help of glucagon-like peptide-1 (GLP-1) medications like \u00a0Ozempic, Mounjaro,\u00a0 and \u00a0Saxenda\u00a0. Research into these medications has garnered attention for their potential implications for individuals struggling with \u00a0alcohol addiction\u00a0.<\/p>\n

Researchers have recently pointed out that individuals taking GLP-1 medications tend to experience a \u00a0delay in the effects\u00a0 of alcohol, leading to a \u00a0decreased desire for alcohol\u00a0. Alex DiFeliceantonio, associate professor and co-director at the \u00a0FBRI’s Center for Health Behaviors Research\u00a0 at Virginia Tech, emphasizes that this phenomenon has only been documented in \u00a0obese patients taking GLP-1 medications\u00a0, and not in healthy individuals. “Previous studies demonstrated a reduction in alcohol consumption solely among those with overweight or obesity,” she points out.<\/p>\n

The findings from a recent pilot study, published in \u00a0Scientific Reports\u00a0, indicate that patients taking \u00a0semaglutide, tirzepatide, and liraglutide\u00a0 as treatments for diabetes and obesity may experience a delayed onset of alcohol’s effects. Participants reported feeling \u00a0less intoxicated\u00a0 after consuming alcohol while on GLP-1 medication.<\/p>\n

Understanding the Mechanism<\/h2>\n

DiFeliceantonio’s initial goal was to study those who consume alcohol without meeting the criteria for alcohol use disorder. She notes that existing studies have explored how \u00a0GLP-1 receptor agonists\u00a0 can potentially reduce alcohol consumption. But what exactly is happening at a biochemical level?<\/p>\n

The key lies in how GLP-1 medications impact the \u00a0absorption and processing of alcohol\u00a0 in the body. DiFeliceantonio explains, “Alcohol must cross the \u00a0blood-brain barrier\u00a0 to exert its psychoactive effects.” When GLP-1 medications are in the system, they can \u00a0slow down alcohol’s entry\u00a0 into the bloodstream, consequently taking longer to affect the central nervous system. Moreover, GLP-1 has been shown to delay \u00a0gastric emptying\u00a0, which means that alcohol absorption into the bloodstream occurs more slowly.<\/p>\n

The researcher illustrates this point by contrasting the effects of drinking a shot of liquor versus slowly sipping a glass of wine. “While it’s the same amount of alcohol, the speed at which it reaches the brain is very different,” she explains. In their study, participants achieved similar breath alcohol levels, yet their \u00a0subjective feelings of intoxication differed\u00a0. This modulation of immediate subjective effects may lead to \u00a0reduced alcohol consumption\u00a0.<\/p>\n

Study Design and Observations<\/h2>\n

In the pilot study, researchers categorized participants based on the specific type of GLP-1 medication they were using\u2014Ozempic, Mounjaro, or Saxenda. All participants received the same \u00a0dose of alcohol\u00a0, calibrated to their weight, and had the same time to consume it. Consequently, any observed effects were likely a result of the GLP-1 agonist consumption.<\/p>\n

The study involved \u00a020 participants\u00a0 with a BMI of 30 or higher, half of whom were on a maintenance dose of a GLP-1 medication and half who were not. Participants fasted prior to the study and received a \u00a0snack bar\u00a0 to standardize caloric intake. Researchers recorded metrics such as \u00a0blood pressure, heart rate, breath alcohol concentration\u00a0, and \u00a0blood glucose levels\u00a0 before and after alcohol consumption.<\/p>\n

After participants consumed alcohol, they rated their feelings of intoxication on a scale from 0 to 10 multiple times over the next hour. Their breath alcohol concentration was measured every thirty minutes until it fell below 0.02%. Researchers did this to gauge both \u00a0physiological and subjective effects\u00a0 of alcohol.<\/p>\n

The study stemmed from anecdotal reports on the social network \u00a0Reddit\u00a0, where users described reduced cravings for alcohol while on diabetes medications. The inspiration for this research initially arose during a faculty retreat at the Fralin Biomedical Research Institute, led by the late Warren Bickel, a known advocate for addiction recovery research.<\/p>\n

Future Implications and Research Directions<\/h2>\n

DiFeliceantonio articulates that this pilot study has laid a strong foundation for future research focused on using GLP-1 medications to moderate alcohol intake. She highlights the necessity for \u00a0subsequent studies\u00a0 comparing GLP-1 effects with other existing medications designed for alcohol use disorder, such as \u00a0naltrexone\u00a0 and \u00a0acamprosate\u00a0.<\/p>\n

\u201cFuture randomized controlled trials should include placebo groups or standard treatment options,\u201d she states. The objective of quickly grasping the impact of GLP-1 receptor agonists on alcohol consumption is clear but demands further exploration.<\/p>\n

When asked about upcoming research, DiFeliceantonio mentions that controlled trials examining the role of GLP-1s in reducing alcohol consumption are currently not underway but plans for numerous future studies are anticipated.<\/p>\n

The ongoing exploration of GLP-1 medications offers a glimpse into a novel approach for addressing alcohol use disorder, emphasizing a growing intersection of metabolic health and behavioral science in modern medicine. As research advances, we may witness groundbreaking strategies that could revolutionize how we view and approach \u00a0alcohol consumption\u00a0.<\/p>\n<\/div>\n


\n
General News – 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Exploring the Future of Alcohol Consumption with GLP-1 Medications Imagine a world where you can enjoy a drink without worrying about \u00a0getting drunk\u00a0. The possibility of \u00a0moderating alcohol consumption\u00a0 may soon become a reality with the help of glucagon-like peptide-1 (GLP-1) medications like \u00a0Ozempic, Mounjaro,\u00a0 and \u00a0Saxenda\u00a0. Research into these medications has garnered attention for […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36400],"tags":[36717,36729,43672,43673,19490,26681],"class_list":["post-177047","post","type-post","status-publish","format-standard","hentry","category-health","tag-ciencia-y-salud","tag-ciencia-y-salud-salud","tag-consumo-alcohol","tag-obesidad","tag-ozempic","tag-salud"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/177047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=177047"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/177047\/revisions"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=177047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=177047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=177047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}